CHARACTERIZATION OF INSULIN-LIKE GROWTH FACTOR-I RECEPTORS IN THE MEDIAN-EMINENCE OF THE BRAIN AND THEIR MODULATION BY FOOD RESTRICTION
CHARACTERIZATION OF INSULIN-LIKE GROWTH FACTOR-I RECEPTORS IN THE MEDIAN-EMINENCE OF THE BRAIN AND THEIR MODULATION BY FOOD RESTRICTION
复制标题
DOI:
10.1210/endo-122-5-1940
复制
发表时间:
1988-05-01
期刊:
影响因子:
4.8
通讯作者:
BASKIN, DG
中科院分区:
文献类型:
--
作者:
BOHANNON, NJ;CORP, ES;BASKIN, DG
High affinity binding sites for 125I-labeled [Thr59]insulin-like growth factor I (IGF-I) were measured in rat median eminence by in vitro autoradiography with slide-mounted sections of frozen rat brain. Specific binding of 0.1 nM iodo-[Thr59]IGF-I to brain slices reached maximum by 12 h at 4 C and was unchanged at 24 h. Densitometry by computer digital image analysis of autoradiographic images indicated that specific biding of iodo-[Thr59]IGF-I to the median eminence was reversible. The specificity of binding was evaluated with competition of iodo-[Thr59]IGF-I with unlabeled [Thr59]IGF-I, rat IGF-II (multiplication-stimulating activity), and porcine insulin. All were recognized by the binding site, but the rank order of potency was [Thr59]IGF-I > IGF-II > insulin. Somatostatin was completely ineffective. Further, an antibody against the rat IGF-II receptor did not block binding of iodo-[Thr59]IGF-I to the median eminence. Fourteen days of food restriction (75% of food intake of controls) resulted in significant weight loss and reduction of plasma immunoreactive IGF-I in six food-restricted rats (0.9 .+-. 0.1 U/ml) compared with values in six controls (2.6 .+-. 0.5 U/ml; P < 0.001). Binding of 125I-labeled [Thr59]IGF-I in the median eminence was significantly increased in the food-restricted rats, primarily due to an increase in the concentration of iodo-[Thr59]IGF-I-binding sites in the median eminence; the affinity (Kd) of binding was unchanged. The results indicate that the median eminence has type I IGF-I receptors, which become more numerous under metabolic conditions associated with decreased caloric intake and lowered plasma IGF-I levels.